144 related articles for article (PubMed ID: 8031055)
21. Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.
Vallée F; LeBel M
Antimicrob Agents Chemother; 1991 Oct; 35(10):2057-64. PubMed ID: 1759827
[TBL] [Abstract][Full Text] [Related]
22. Antibacterial activity of ciprofloxacin administered intravenously in a pharmacodynamic in vitro model.
Esposito S; Jansen A
Int J Clin Pharmacol Res; 1991; 11(4):193-9. PubMed ID: 1813438
[TBL] [Abstract][Full Text] [Related]
23. Ciprofloxacin: a comparative evaluation of its bactericidal activity in human serum against four enterobacterial species.
Weiss D; Trautmann M; Wagner J; Borner K; Hahn H
Drugs Exp Clin Res; 1986; 12(11):889-94. PubMed ID: 3545730
[TBL] [Abstract][Full Text] [Related]
24. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.
Catchpole C; Andrews JM; Woodcock J; Wise R
J Antimicrob Chemother; 1994 Jan; 33(1):103-10. PubMed ID: 8157550
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
Kalman D; Barriere SL; Johnson BL
Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.
Petitjean O; Pangon B; Brion N; Tod M; Chaplain C; Le Gros V; Louchahi K; Allouch P
Antimicrob Agents Chemother; 1993 Apr; 37(4):737-40. PubMed ID: 8494368
[TBL] [Abstract][Full Text] [Related]
27. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Hyatt JM; Nix DE; Stratton CW; Schentag JJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.
Dudley MN; Mandler HD; Gilbert D; Ericson J; Mayer KH; Zinner SH
Am J Med; 1987 Apr; 82(4A):363-8. PubMed ID: 3555061
[TBL] [Abstract][Full Text] [Related]
29. Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.
Weinstein MP; Deeter RG; Swanson KA; Gross JS
Antimicrob Agents Chemother; 1991 Nov; 35(11):2352-8. PubMed ID: 1804008
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.
Lipman J; Scribante J; Gous AG; Hon H; Tshukutsoane S
Antimicrob Agents Chemother; 1998 Sep; 42(9):2235-9. PubMed ID: 9736541
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle.
Elias G; Lee JS; Hwang MH; Park YS; Cho KH; Kim YH; Park SC
J Vet Pharmacol Ther; 2009 Jun; 32(3):219-28. PubMed ID: 19646085
[TBL] [Abstract][Full Text] [Related]
33. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
34. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.
Leighton A; Gottlieb AB; Dorr MB; Jabes D; Mosconi G; VanSaders C; Mroszczak EJ; Campbell KC; Kelly E
Antimicrob Agents Chemother; 2004 Mar; 48(3):940-5. PubMed ID: 14982787
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.
Drusano GL; Standiford HC; Fitzpatrick B; Leslie J; Tangtatsawasdi P; Ryan P; Tatem B; Moody MR; Schimpff SC
Antimicrob Agents Chemother; 1984 Sep; 26(3):388-93. PubMed ID: 6391372
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
38. Intravenous pharmacokinetics of ciprofloxacin in goats.
García Ovando H; Gorla N; Poloni G; Trotti N; Prieto G; Errecalde C
Int J Antimicrob Agents; 2000 Jun; 15(1):77-9. PubMed ID: 10856681
[TBL] [Abstract][Full Text] [Related]
39. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.
Chin NX; Neu HC
Am J Med; 1987 Apr; 82(4A):58-62. PubMed ID: 3578330
[TBL] [Abstract][Full Text] [Related]
40. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
Parte AC; Smith JT
Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
